Mineralys Therapeutics (MLYS) CMO exercises options, sells 416 shares

Q: What insider transaction did Mineralys Therapeutics (MLYS) report?

Mineralys reported that Chief Medical Officer David Malcom Rodman exercised stock options for 416 shares at $15.4400 per share and sold 416 common shares at $26.5300 on the same day, reflecting an exercise-and-sale sequence rather than a simple open-market purchase.

Q: How many Mineralys Therapeutics (MLYS) shares did the CMO sell and at what price?

The CMO sold 416 shares of Mineralys common stock at $26.5300 per share. These shares were obtained through the same-day exercise of stock options and the sale was reported as a standard “S” code transaction in the Form 4 filing.

Q: At what price were the Mineralys Therapeutics (MLYS) stock options exercised?

The stock options were exercised at an exercise price of $15.4400 per share . Exercising converted the derivative position into 416 shares of common stock , which were then sold at $26.5300 per share as part of the same transaction sequence.

Q: How many Mineralys Therapeutics (MLYS) stock options does the CMO retain from this grant?

Following the reported exercise, the CMO retains 3334 stock options from this grant. These options relate to the same award that vested over time and are reported with an expiration date of 2033-03-17 , indicating a remaining derivative position.

Q: What is the vesting schedule of the Mineralys Therapeutics (MLYS) stock option grant?

A footnote explains the option vested 25% of the underlying shares on the first anniversary of the grant date. The remaining shares then vested in 36 substantially equal monthly installments , creating a gradual, time-based vesting structure for the award.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Mineralys Therapeutics Chief Medical Officer David Malcom Rodman exercised stock options for 416 shares of common stock at $15.4400 per share and on the same day sold 416 shares at $26.5300, all under a Rule 10b5-1 trading plan adopted on October 6, 2025. After the exercise, 3334 stock options from this grant remain outstanding, expiring on 2033-03-17.

Insider Trade Summary 10b5-1

Exercise and Sale: 416 shares ($5K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Rodman David Malcom

Role Chief Medical Officer

Sold 416 shs ($11K)

Approx. gross sale proceeds $11K

Approx. exercise cost $6K

Approx. pre-tax spread $5K

Type	Security	Shares	Price	Value
Exercise	Stock Option ^{F1, F2}	416	$0.00	$0.00
Exercise	Common Stock ^F1	416	$15.44	$6K
Sale	Common Stock ^F1	416	$26.53	$11K

Holdings After Transaction: Stock Option — 3,334 shares (Direct); Common Stock — 51,384 shares (Direct)

Footnotes (2)

F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
F2. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

Key Figures

Shares sold: 416 shares Sale price: $26.5300 per share Options exercised: 416 shares +3 more

6 metrics

Shares sold 416 shares Common stock sold on 2026-07-17

Sale price $26.5300 per share Price for 416 common shares sold

Options exercised 416 shares Underlying common shares from stock option exercise on 2026-07-17

Exercise price $15.4400 per share Conversion price of stock option exercised

Options remaining 3334 shares Stock options from this grant remaining after exercise

Option expiration 2033-03-17 Expiration date of the reported stock option grant

Key Terms

Rule 10b5-1 trading plan, stock option, Exercise or conversion of derivative security, substantially equal monthly installments

4 terms

Rule 10b5-1 trading plan financial

"These transactions were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

stock option financial

"The stock option vested as to 25% of the underlying shares"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Exercise or conversion of derivative security financial

"transaction code description: Exercise or conversion of derivative security"

substantially equal monthly installments financial

"remaining shares vesting in 36 substantially equal monthly installments"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/20/2026 - 09:00 PM Accepted by SEC EDGAR 07/20/2026 - 09:00 PM

FAQ

What insider transaction did Mineralys Therapeutics (MLYS) report?

Mineralys reported that Chief Medical Officer David Malcom Rodman exercised stock options for 416 shares at $15.4400 per share and sold 416 common shares at $26.5300 on the same day, reflecting an exercise-and-sale sequence rather than a simple open-market purchase.

How many Mineralys Therapeutics (MLYS) shares did the CMO sell and at what price?

The CMO sold 416 shares of Mineralys common stock at $26.5300 per share. These shares were obtained through the same-day exercise of stock options and the sale was reported as a standard “S” code transaction in the Form 4 filing.

At what price were the Mineralys Therapeutics (MLYS) stock options exercised?

The stock options were exercised at an exercise price of $15.4400 per share. Exercising converted the derivative position into 416 shares of common stock, which were then sold at $26.5300 per share as part of the same transaction sequence.

Was the Mineralys Therapeutics (MLYS) insider trade under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were effected under a Rule 10b5-1 trading plan adopted on October 6, 2025. Such pre-arranged plans automate trading activity according to preset instructions rather than discretionary timing decisions by the insider.

How many Mineralys Therapeutics (MLYS) stock options does the CMO retain from this grant?

Following the reported exercise, the CMO retains 3334 stock options from this grant. These options relate to the same award that vested over time and are reported with an expiration date of 2033-03-17, indicating a remaining derivative position.

What is the vesting schedule of the Mineralys Therapeutics (MLYS) stock option grant?

A footnote explains the option vested 25% of the underlying shares on the first anniversary of the grant date. The remaining shares then vested in 36 substantially equal monthly installments, creating a gradual, time-based vesting structure for the award.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rodman David Malcom

(Last)

(First)

(Middle)

150 N. RADNOR CHESTER ROAD

SUITE F200

(Street)

RADNOR

PENNSYLVANIA

19087

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/17/2026		M⁽¹⁾		416	A	$15.44	51,800	D
Common Stock	07/17/2026		S⁽¹⁾		416	D	$26.53	51,384	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option	$15.44	07/17/2026		M⁽¹⁾			416	⁽²⁾	03/17/2033	Common Stock	416	$0	3,334	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

2. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

Remarks:

	/s/ Adam Levy, Attorney-in-fact	07/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR